Evidence map›Paper›PMID 27455456›Full record

ArticlePharmacotherapy2017

Effect of Prescription Drug Coupons on Statin Utilization and Expenditures: A Retrospective Cohort Study.

Matthew Daubresse, Martin Andersen, Kevin R Riggs, G Caleb Alexander

Open access · greenAbstract read
In one paragraph

Article in Pharmacotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
10.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Impact of brand drug discount cards on private insurer, government and patient expenditures.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2019
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Matthew DaubresseCenter for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore, Maryland.
Martin AndersenDepartment of Economics, University of North Carolina at Greensboro, Greensboro, North Carolina.
Kevin R RiggsCenter for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore, Maryland.
G Caleb AlexanderCenter for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore, Maryland.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversity of North Carolina at Greensboro · US

Funding

BEHAVIORAL RESEARCH IN HEART &VASCULAR DISEASET32HL007180 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI MARUTHUR, NISA M · 1985 to 2020
$11.4M
Televised Direct to Consumer Pharmaceutical Advertising and Patient OutcomesR01HL107345 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALEXANDER, G. CALEB, EMERY, SHERRY L · 2011 to 2014
$3.0M
NHLBI NIH HHS R01 HL107345NHLBI NIH HHS T32 HL007180
6 · The paper itself

Abstract

importanceDrug coupons are widely used, but their effects are not well understood.

objectiveTo quantify the effect of coupons on statin use and expenditures.

designRetrospective cohort analysis of IMS Health LRx LifeLink database.

settingU.S. retail pharmacy transactions.

participantsIncident statin users who initiated branded atorvastatin or rosuvastatin between June 2006 and February 2013. MAIN OUTCOMES AND MEASURES: Monthly statin utilization (pill-days of therapy), switching (filling a different statin), termination (failure to refill statin for 6 mo), and out-of-pocket and total costs.

resultsOf 1.1 million incident atorvastatin and rosuvastatin users, 2% used a coupon for at least one statin fill. At 1 year, compared with noncoupon users, those who used a statin coupon on their first fill were dispensed an equal number of monthly pill-days (23.7 vs 23.8), were less likely to switch statins (14.4% vs 16.3%), and were less likely to have terminated statin therapy (31.3% vs 39.2%). At 4 years, coupon users were more likely to have switched (45.5% vs 40.8%) and less likely to have terminated statin therapy (50.6% vs 61.1%) compared with noncoupon users. Those who used greater numbers of coupons were substantially less likely to switch and terminate statin therapies. Monthly out-of-pocket costs were lower among coupon than noncoupon users at 1 year ($9.7 vs $15.1), but total monthly costs were qualitatively similar ($115.5 vs $116.9). At 4 years, monthly out-of-pocket costs among coupon users remained lower ($14.3 vs $16.6) compared with noncoupon users. Sensitivity analyses supported the main results.

conclusionsCoupons for branded statins are associated with higher utilization and lower rates of discontinuation and short-term switching to other statin products.

Indexed as

Drug CostsHealth ExpendituresAdultAgedDrug UtilizationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrescription DrugsRetrospective StudiesHydroxymethylglutaryl-CoA Reductase InhibitorsPrescription DrugsCopaycostscouponsstatin utilization

Identifiers

PMID27455456
PMCPMC5243177
OpenAlexW2485336461

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.